1 February 2024 in American Journal of Physiology-Heart and Circulatory Physiology
Dystrophin deficiency in cardiomyocytes leads to abnormally reduced Na+ currents. These can be rescued by long-term empagliflozin treatment.
3 August 2021 in Journal of Cardiovascular Pharmacology and Therapeutics
Background: Vascular stiffness and endothelial dysfunction are accelerated by acute myocardial infarction (AMI) and subsequently increase the risk for recurrent coronary events. Aim: To explore whether remote ischemic perconditioning (RIPerc) protects against coronary and aorta endothelial dysfunction as well as aortic stiffness following AMI. Methods: Male OFA-1 rats were subjected to 30 min of occlusion of the left anterior descending artery (LAD) followed by reperfusion either 3 or 28 days with or without RIPerc. Three groups: (1) sham operated (Sham, without LAD occlusion); (2) myocardial ischemia and reperfusion (MIR) and (3) MIR + RIPerc group with 3 cycles of 5 minutes of IR on hindlimb performed during myocardial ischemia were used. Assessment of vascular reactivity in isolated septal coronary arteries (non-occluded) and aortic rings as well as aortic stiffness was assessed by wire myography either 3 or 28 days after AMI, respectively. Markers of pro-inflammatory cytokines, adhesion molecules were assessed by RT-qPCR and ELISA. Results: MIR promotes impaired endothelial-dependent relaxation in septal coronary artery segments, increased aortic stiffness and adverse left ventricular remodeling. These changes were markedly attenuated in rats treated with RIPerc and associated with a significant decline in P-selectin, IL-6 and TNF-α expression either in infarcted or non-infarcted myocardial tissue samples. Conclusions: Our study for the first time demonstrated that RIPerc alleviates MIR-induced coronary artery endothelial dysfunction in non-occluded artery segments and attenuates aortic stiffness in rats. The vascular protective effects of RIPerc are associated with ameliorated inflammation and might therefore be caused by reduced inflammatory signaling.
13 December 2025 in The American Journal of Pathology
AGAna I. Antunes Goncalves
+9
Duchenne muscular dystrophy (DMD) is a severe X-linked disorder with progressive myofiber degeneration and fibrosis from dystrophin deficiency. Current therapies are largely supportive with limited anti-fibrotic benefit, prompting new strategies. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) show emerging anti-fibrotic and anti-inflammatory effects. Open-access proteomic and transcriptomic data sets were integrated for in silico analyses, including differential gene expression, weighted gene co-expression network analysis, and pathway enrichment, to identify dysregulated pathways potentially reversible by SGLT2i. Immune cell composition was estimated using CIBERSORTx in human and murine data sets. Therapeutic effects were tested with empagliflozin (EMPA) in mdx mice (30 mg/kg per day for 4 weeks, starting at 12 weeks) and DMDmdx rats (10 mg/kg per day for 4 months, starting at 5 months), with vehicle controls. Validation used quantitative RT-PCR, grip-strength testing, and histologic fibrosis staining. Analyses highlighted dysregulated extracellular matrix organization, cytokine signaling, and immune responses. Forty overlapping genes were identified; hub genes included COL3A1, COL5A2, and TGFB1. EMPA reduced Tgfb1 expression in DMD rats and significantly decreased collagen deposition in skeletal muscle. Functional testing showed longer grip duration in EMPA-treated mice. Immune profiling revealed shifts in T cells and macrophages, indicating immunomodulation. Findings were consistent across species and data modalities analyzed. These results demonstrate that EMPA modulates fibrosis, inflammation, and muscle endurance in DMD models. These data support repurposing SGLT2i as a promising therapeutic strategy for DMD.
1 September 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Dystrophin deficiency in cardiomyocytes leads to diminished peak Na currents. These can be fully rescued by long-term treatment with empagliflozin via pharmacochaperoning of Nav1.5 channels.
29 November 2025 in Biomedicine & Pharmacotherapy
This experimental study investigates the potential of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin to enhance cardiac hemodynamic and metabolism function following ischemia/reperfusion (I/R) after cold cardioplegic arrest. Hearts of adult male C57BL/6 J mice were excised and mounted on an isolated working heart system. Cold ischemia (100 min) was induced using St. Thomas' #2 cardioplegia, applied every 20 min, followed by 30 min of reperfusion. Continuous monitoring of cardiac parameters was performed. The experimental groups were the following (1) cold cardioplegic arrest as control (n = 12), (2) dapagliflozin applied to perfusion buffer 30 min prior to ischemia (n = 16), (3) arrested hearts receiving dapagliflozin as an adjunct to cardioplegia (n = 13), and (4) no-arrested, no-treated hearts (n = 6). Post-protocol, biopsies of hearts were frozen for subsequent metabolic and RT-qPCR analysis. Additionally, cell culture experiments on HUVECS and cardiac myoblasts were performed. Cold I/R markedly reduced systolic and diastolic function. Notably, dapagliflozin administered before ischemia significantly improved left ventricular recovery by enhancing contractility, aortic flow, and left ventricle diastolic function, whereas adding dapagliflozin only to the cardioplegic solution did not yield similar effects. High-energy phosphate (HEP) measurements revealed a statistically significant increase of myocardial energy charge in hearts treated with dapagliflozin via cardioplegia. These functional and metabolic findings were supported by improved cell viability and higher HEP content in HUVECS and cardiac myoblasts, when pre-treated with SGLT2i. Our findings underscore the potential of SGLT2i to improve hemodynamic recovery following cardioplegic arrest, supporting further exploration of dapagliflozin as novel myocardial protective regimen in cardiac surgery.
1 September 2025 in American Journal of Physiology-Heart and Circulatory Physiology
Dystrophin deficiency in cardiomyocytes leads to abnormally reduced Na currents. These can be rescued by inhibition of the expression of tenascin C.